Ratio Therapeutics Inc.
PrivateLast Round
Series B
Jan 17, 2024
Total Funding Raised
$90M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ratio Therapeutics Inc. is a biotechnology company that develops next-generation precision radiopharmaceuticals for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ratio Therapeutics Inc. Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Ratio Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 17, 2024 | ||||
| Series A | Feb 1, 2023 | ||||
| Seed | Jun 10, 2022 |
Ratio Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Technology Licensing at Cornell University | Series B |
| Duquesne Family Office | Series A |
| Pags Group | Series B |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A, Series B |
| Catalio Capital Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
Colin Hayward appointed as the new Chief Medical Officer.
- Jun 13, 2025
Partnered with Macrocyclics for radiopharmaceutical chelator platform.
Ratio Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ratio Therapeutics Inc.'s valuation, stock price, and market status.